79 related articles for article (PubMed ID: 10070872)
1. Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).
Kuin A; Rutgers M; van der Valk MA; Beijnen JH; Smets LA
Br J Cancer; 1999 Feb; 79(5-6):802-6. PubMed ID: 10070872
[TBL] [Abstract][Full Text] [Related]
2. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine.
Kuin A; Aalders M; van der Valk MA; Frey A; Schmidt HH; Smets LA
Cancer Chemother Pharmacol; 1998; 42(1):37-45. PubMed ID: 9619756
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
4. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.
Miano M; Garaventa A; Pizzitola MR; Piccolo MS; Dallorso S; Villavecchia GP; Bertolazzi C; Cabria M; De Bernardi B
Bone Marrow Transplant; 2001 Mar; 27(6):571-4. PubMed ID: 11319584
[TBL] [Abstract][Full Text] [Related]
5. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
6. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
8. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
[TBL] [Abstract][Full Text] [Related]
9. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
10. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
11. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
14. Oral topotecan: bioavailablity and effect of food co-administration.
Herben VM; Rosing H; ten Bokkel Huinink WW; van Zomeren DM; Batchelor D; Doyle E; Beusenberg FD; Beijnen JH; Schellens JH
Br J Cancer; 1999 Jul; 80(9):1380-6. PubMed ID: 10424739
[TBL] [Abstract][Full Text] [Related]
15. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
16. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
17. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia.
Kuin A; Smets L; Volk T; Paans A; Adams G; Atema A; Jähde E; Maas A; Rajewsky MF; Visser G
Cancer Res; 1994 Jul; 54(14):3785-92. PubMed ID: 8033098
[TBL] [Abstract][Full Text] [Related]
18. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
20. Excretion of volatile ¹³¹I from rats following administration of Na¹³¹I or MIBG-¹³¹I.
Li C; Sadi B; Wyatt H; Bugden M; Wilkinson D; Cornett J; Kramer GH
Radiat Prot Dosimetry; 2012 Jan; 148(2):143-8. PubMed ID: 21307022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
